Clinical Trials List
2018-06-11 - 2023-01-31
Phase III
Terminated7
ICD-10C54.1
Malignant neoplasm of endometrium
ICD-9182.0
Malignant neoplasm of corpus uteri, except isthmus
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- Huann-Cheng Horng Division of Obstetrics & Gynecology
- Yen-Hou Chang Division of Obstetrics & Gynecology
- Yi-Jen Chen Division of Obstetrics & Gynecology
- Chi-Mu Chuang Division of Obstetrics & Gynecology
- 沈書慧 Division of Radiology
The Actual Total Number of Participants Enrolled
5 Stop recruiting
Audit
None
Co-Principal Investigator
- 童寶玲 Division of Obstetrics & Gynecology
- 戴依柔 Division of Obstetrics & Gynecology
- Wen-Fang Cheng Division of Obstetrics & Gynecology
- YING-CHENG CHIANG Division of Obstetrics & Gynecology
- 郭冠廷 Division of Others
- 陳祈安 Division of Obstetrics & Gynecology
- 陳宇立 Division of Obstetrics & Gynecology
- CHI-HAU CHEN CHI-HAU CHEN Division of Obstetrics & Gynecology
- 施怡倫 Division of Radiology
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Audit
None
The Actual Total Number of Participants Enrolled
0 Stop recruiting
The Actual Total Number of Participants Enrolled
0 Stop recruiting
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
- 黃寬仁 Division of Obstetrics & Gynecology
- 周宏學 Division of Obstetrics & Gynecology
- Angel Chao Division of Obstetrics & Gynecology
- 周宏學 Division of Obstetrics & Gynecology
- Chyong-Huey Lai Division of Obstetrics & Gynecology
- 黃彥綾 Division of Radiology
- Huei-Jean Huang Division of Obstetrics & Gynecology
The Actual Total Number of Participants Enrolled
0 Stop recruiting
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
40 participants
-
Global
780 participants
